Imagine trying to find a key for a lock by testing thousands of tiny metal scraps instead of full keys. Once a scrap fits a small part of the lock, scientists use AI and high-tech imaging to grow that scrap into a perfect key. This method finds starting points for new medicines much faster than traditional trial-and-error screening.
Traditional drug discovery screens hundreds of thousands of molecules, which is slow and often inefficient. There is a need for faster, more accurate ways to identify small chemical starting points that can be reliably grown into high-affinity drugs.
A high-density fragment screening proof-of-concept and the first implementation of a Fragment-Based Drug Discovery (FBDD) repository coordinated by EBI.
If you are a drug discovery firm dealing with slow target identification and high failure rates — this project developed AI-guided workflows and new instrumentation that increase the speed and accuracy of finding drug starting points.
If you are a biotech startup dealing with limited access to expensive structural biology equipment — this project developed new workflows available at European RIs that lower the barrier to early-phase structure-based drug discovery.
If you are a lab equipment manufacturer dealing with a lack of competitive drug-design tools — this project developed new instrumentation for commercialization to increase the technological competitiveness of European industry.
Based on available project data, specific pricing is not mentioned, but the project aims to commercialize new instruments to increase European industrial competitiveness.
Yes, the project focuses on enhancing the throughput of X-Ray based screening pipelines and establishing high-density screening proofs-of-concept for industrial use.
Based on available project data, the project intends to commercialize new instruments, though specific licensing terms are not provided.
The project creates a framework for the objective evaluation of AI in drug design and uses structural biology data to feed AI methodologies that guide medicinal chemistry.
The project period runs from 2023-02-01 to 2027-01-31, indicating that full deployment of tools and workflows will occur toward the end of this window.
The project features a strong industrial base with 8 industry partners (31% ratio) and 26 total partners across 11 countries. The collaboration is anchored by four major European research infrastructures (ESRF, EU-OPENSCREEN, ELIXIR, and Instruct-ERIC), ensuring that the developed tools are tested in world-class facilities before commercialization.
Contact INSTRUCT-ERIC in the UK for technical inquiries regarding FBDD workflows.
Contact us to identify potential licensing opportunities for the new FBDD instrumentation.
